FDA Seeks Halt of Cymbalta Promotion
The U.S. Food and Drug Administration (FDA) has determined that a professional mailer on Cymbalta from manufacturer Eli Lilly and Co. is "false and misleading" in that it "overstates the efficacy of Cymbalta and omits some of the most serious and important risk information associated with its use" in violation of federal law. FDA has ordered Lilly to cease dissemination of these promotional materials. Cymbalta has been approved for treatment of major depressive disorder, management of pain associated with diabetes, and treatment of generalized anxiety disorder.
- FDA Letter to Eli Lilly and Co. [PDF file]
- Wall Street Journal: FDA Asks Eli Lilly to Stop Promotion of Cymbalta
- Cymbalta Safety Information (Eli Lilly and Co.)
- Duloxetine (marketed as Cymbalta) Information (FDA)
You Don’t Have To Solve This on Your Own – Get a Lawyer’s Help
Meeting with a lawyer can help you understand your options and how to best protect your rights. Visit our attorney directory to find a lawyer near you who can help.
Or contact an attorney near you: